All In Biotech

Drug Trial Radar · NCT03057769

Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin

Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin: A Multi-center, Double-blind, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 3,300 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,300

Actual

Start

Feb 1, 2017

Primary completion

Oct 26, 2017

Study completion Oct 26, 2017

Sponsor

Lead sponsor
Air Force Military Medical University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. It accounts for substantial morbidity and represents a substantial cost to health-care systems. European Society of Gastrointestinal Endoscopy and Japanese Society of Hepato-Biliary-Pancreatic surgery guidelines and recently large-scale RCT recommended routine use of NSAIDs indomethacin rectally before ERCP. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit prostaglandin synthesis, phospholipase A2 activity, and neutrophil/endothelial cell attachment, which is believed to play a key role in the pathogenesis of acute pancreatitis. Other possible mechanisms have been suggested in the occurrence of pancreatitis. Papillary edema caused by manipulations during cannulation or endoscopic treatment has received the most attention. The papillary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. Topical application of epinephrine on the papilla may reduce papillary edema by decreasing capillary permeability or by relaxing the sphincter of Oddi. A meta-analysis (including 2 existing RCTs and post-hoc analysis of our previous study) of papillary epinephrine spraying compared with saline spraying or no intervention indicates a potential relative risk reduction of PEP (RR 0.34, 95%CI 0.19-0.61). Papillary epinephrine spraying may be an inexpensive and convenient alternative for prevention of post-ERCP pancreatitis. A large pragmatic RCT to determine whether routine using papillary epinephrine spraying can reduce post-ERCP pancreatitis is needed.

Conditions

  • Pancreatitis
  • Endoscopic Retrograde Cholangiopancreatography

Interventions

  • Papillary epinephrine sprayingDrug

    All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.

  • Papillary saline sprayingDrug

    All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.

  • IndomethacinDrug

    All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall post-ERCP pancreatitis (PEP)Time frame: 30 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University

    Yinchuan, China

  • Department of Gastroenterology, Successful Hospital of Xiamen university

    Xiamen, Fujian, China

  • Department of Gastroenterology, Zhongshan Hospital of Xiamen university

    Xiamen, Fujian, China

  • Department of General Surgery, The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Endoscopy Center, Ankang Central Hospital

    Ankang, Shaanxi, China

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shaanxi, China

  • Department of Gastroenterology, No. 451 Hospital

    Xi'an, Shaanxi, China

  • Department of Gastroenterology, The First Affiliated Hospital of the Medical College, Shihezi University

    Shihezi, Xinjiang, China

  • Department of Gastroenterology, Urumqi General Hospital of Lanzhou Military Region

    Ürümqi, Xinjiang, China

  • Department of Gastroenterology, Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.